AMAM Company Profile and Key Details
Ambrx Biopharma Inc.
AMAM Stock Price Chart
Stock Price Today
Ambrx Biopharma Inc. (AMAM) stock surged +0.07%, trading at $28.00 on NYSE, up from the previous close of $27.98. The stock opened at $27.99, fluctuating between $27.98 and $28.00 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
Company Information
| Employees | 87 |
| Beta | -2.36 |
| Sales or Revenue | $7.40M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Ambrx Biopharma Inc. (NYSE: AMAM) stock price is $28.00 in the last trading session. During the trading session, AMAM stock reached the peak price of $28.00 while $27.98 was the lowest point it dropped to. The percentage change in AMAM stock occurred in the recent session was 0.07% while the dollar amount for the price change in AMAM stock was $0.02.
The NYSE listed AMAM is part of Biotechnology industry that operates in the broader Healthcare sector. Ambrx Biopharma Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Ying J. Buechler Ph.D.
Executive Director of Biologics Devel. & Manufacturing
Dr. Shawn Shao-Hui Zhang Ph.D.
Chief Scientific Officer & GM of China
Ms. Sonja Nelson CPA
Chief Financial Officer
Mr. Daniel J. O'Connor J.D.
Chief Executive Officer, Pres & Director
Ms. Renu Vaish M.Sc.
Chief Regulatory Officer
Dr. Sandra Aung Ph.D.
Chief Clinical Officer
Ms. Sonja Nelson C.P.A.
Chief Financial Officer
Mr. Andrew P. Aromando
Chief Operating Officer
Mr. Jared Kelly
Senior Vice President, Gen. Counsel & Corporation Sec.
AMAM's closing price is 327.48% higher than its 52-week low of $6.55 where as its distance from 52-week high of $28.15 is -0.53%.
Number of AMAM employees currently stands at 87.
Official Website of AMAM is: https://ambrx.com
AMAM could be contacted at phone 858 875 2400 and can also be accessed through its website. AMAM operates from 10975 North Torrey Pines Road, La Jolla, CA 92037, United States.
AMAM stock volume for the day was 1.42M shares. The average number of AMAM shares traded daily for last 3 months was 1.94M.
The market value of AMAM currently stands at $1.77B with its latest stock price at $28.00 and 63.29M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com